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A B S T R A C T
Microglia have emerged as a critical component of neurodegenerative diseases. Genetic manipulation of mi-
croglia can elucidate their functional impact in disease. In neuroscience, recombinant viruses such as lentiviruses
and adeno-associated viruses (AAVs) have been successfully used to target various cell types in the brain, al-
though eﬀective transduction of microglia is rare. In this review, we provide a short background of lentiviruses
and AAVs, and strategies for designing recombinant viral vectors. Then, we will summarize recent literature on
successful microglial transductions in vitro and in vivo, and discuss the current challenges. Finally, we provide
guidelines for reporting the eﬃciency and speciﬁcity of viral targeting in microglia, which will enable the
microglial research community to assess and improve methodologies for future studies.
1. Introduction
Microglia, the immune cells resident in the brain, have emerged as a
critical component in neurodegenerative diseases such as Alzheimer’s
and Parkinson’s disease [1–3]. They express several disease-associated
genes, therefore modulating these genes will provide important biolo-
gical insights. Because microglial function depends on the neuronal
surrounding, such studies would ideally be performed in vivo. In recent
decades, recombinant DNA vectors have enabled scientists to direct
gene transcription in a cell type-dependent manner. Transfection re-
agents or electroporation methods introduce DNA in vitro but are dif-
ﬁcult to translate to an in vivo environment. Transgenic mouse models
can partially overcome this but are a less desirable option, combining
high costs and time commitment with unpredictable success.
Employing viruses as messengers of genetic cargo has become the
method of choice for targeting cells in vivo because it enables cell-spe-
ciﬁc delivery of genetic material within a short time period. The two
main components of a viral-based gene delivery system are: ﬁrst, the
packaging elements consisting of structural proteins and enzymes to
generate a virus; and, second, the transfer vector encoding the gene-of-
interest driven under a cell type-speciﬁc promoter. Both vector com-
ponents are transfected into a cell line, but only the gene-of-interest
encoded on the transfer vector is packaged into the viral particles
(virions). This distinguishes replication-incompetent virions that
transduce a host cell, from a replicative wildtype virus, which infects
host cells. To date, rabies, herpes simplex, adeno-, lenti-, and adeno-
associated viruses (AAV) have been successfully used by the neu-
roscience community to visualize and optogenetically manipulate
neuronal circuits in vivo [4,5]. For basic research, lentiviruses and AAVs
have proven superior, oﬀering eﬃcient tissue transduction with no
immediate immune response or cytotoxicity [5,6].
In this review, we explain the basic biology of lentiviruses and
AAVs, and introduce strategies for generating viral vectors. We then
review recent literature describing successful microglial transduction in
vitro and in vivo, and outline the challenges for achieving viral eﬃciency
and speciﬁcity in microglia. Finally, we provide a comparison between
viral types and propose standardized measures for reporting microglial
transduction experiments.
2. Lentivirus
Lentiviruses belong to the Retroviridae family and are capable of
transducing both non-dividing and dividing cells, which distinguishes
them from retroviruses [7–9]. The genome consists of two copies of
(+)-single-stranded RNA, enclosed in a capsid with structural and en-
zymatic proteins. These include reverse transcriptase, which converts
RNA into double-stranded (ds) DNA, and the DNA integrase, re-
sponsible for integrating the dsDNA into the host genome [10]. To-
gether, these components constitute the viral core, which is further
surrounded by an envelope generated during the budding process from
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the host cell membrane, which harbors the viral receptors (Fig. 1).
Human immunodeﬁciency virus type-1 (HIV-1) is the most promi-
nent lentivirus whose genome is well described (Fig. 2a). Its genes gag,
pol, and env, encode structural core proteins, reverse transcriptase and
integrase, and envelope glycoproteins, respectively. Tat and rev are
involved in viral replication: tat initiates viral genome transcription and
is driven by the long terminal repeats; rev facilitates the nuclear export
of the viral mRNA and is regulated by the rev-responsive element. The
packaging signal (Ψ) is critical for incorporating the viral genome into
the capsid. Additionally, the HIV-1 genome contains virulence factors
vif, vpr, vpu, and nef that interfere with the host defense mechanism and
are included in the assembled virion [10].
2.1. Design and production of lentiviral vectors
The HIV-1 genome serves as a starting point for assembling a virion
containing the transfer vector. The ﬁrst generation of lentiviral vectors
encoded all the packaging elements on a single vector, which posed a
high biosafety risk [7]. Removing the virulence factors and separating
the envelope from the packaging vector improved safety and enhanced
viral replication without interfering with the production of functional
HIV-1-based virions (Fig. 2b) [11]. Moreover, the 3’LTR contained a U3
deletion to abolish promoter activity for viral genome replication, and
to self-inactivate the vector without aﬀecting the virion titer or trans-
gene expression [12–14]. The third, and currently preferred, generation
singled out rev from the packaging vector, and replaced tat with a
constitutive promoter upstream of the transfer vector (Fig. 2c) [15].
The viral envelope glycoproteins determine the lentiviral target site
on the host membrane [10]. Instead of using the HIV-1 envelope gp160,
which would only target cells expressing the CD4 receptor, HIV-1 can
be pseudotyped with envelope glycoproteins from other viral species
such as the rabies or vesicular stomatitis viruses. This increases cellular
tropism and virus stability [16]. Commonly, the HIV-1 viral core is
pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-G),
which binds to the widely expressed low-density lipoprotein (LDL) re-
ceptor [17,18].
2.2. Lentiviral transduction of microglia
The ﬁrst attempts to achieve lentiviral transduction of microglia
were in primary microglial cultures [19–22]. Balcaitis et al. generated
an HIV-1/VSV-G with a transfer vector encoding for GFP under the
murine stem cell virus promoter [20]. Within 72 h after applying the
virus to a mouse microglial culture, the authors found improved
Fig. 1. Lentiviral production (Step I) and transduction (Step II). Virus packaging cell line is transfected with envelope, transfer, and packaging vectors (1). (2) The
transcribed mRNAs for the envelope, transfer, and packaging vectors are translated into: (2a) viral envelope proteins that are sorted to the cell membrane via the
endoplasmic reticulum; (2b) single-stranded RNA viral genome; (2c) viral structural proteins and enzymes, respectively. All three components are assembled into
viral particles (3a), which bud from the host cell membrane (3b). (4) Viral particles attach to the host cell surface receptors using the envelope protein. (5) Fusion of
viral with host plasma membrane releases structural, enzymatic proteins, and viral core. (6) Viral RNA is reverse transcribed to double-stranded DNA that then forms
a pre-integration complex with the integrase (7), which passes the nuclear pore complex (8), and catalyzes viral DNA integration into the host genome (9). (10) The
transfer vector promoter drives transgene expression.
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transduction as the ratio of virus to target cells (MOI) increased. Jiang
et al. reported similar transduction eﬃciencies of 25% with MOI= 2.5,
55% with MOI= 5, 10, or 20, and 99% with MOI=50 or 100 in rat
microglia [21]. Microglial morphology was indistinguishable between
control and MOI= 5, but MOI > 50 resulted in apoptosis starting from
day 4.
The ﬁrst in vivo lentiviral microglial transduction study was by
Åkerblom et al., who transduced microglia in the rat striatum using self-
inactivating-HIV-1 VSV-G-pseudotyped virions (SIN-HIV-1/VSV-G)
[23]. They designed a transfer vector that encoded GFP under the
ubiquitous phosphoglycerate kinase (PGK) promoter (PGK-GFP). To
increase microglial speciﬁcity, the authors took advantage of an ob-
servation that there is no microRNA-9 expression in microglia, but it is
commonly found in other cell types. By introducing four tandem-re-
peats of the microRNA-9 binding site (4miR.T) in the 3’UTR of GFP, the
endogenous microRNA-9 sequesters GFP mRNA in all cells except mi-
croglia. Indeed, the authors observed 75% of Iba+-microglia to be
GFP+; however, the transduction eﬃciency was not quantiﬁed, and
there was no ﬁeld-of-view image of the striatum to support the high
transduction rate reported [23].
In a follow-up study, Brawek et al. performed calcium imaging of
microglia in the mouse somatosensory cortex [24]. The authors used
the previously described SIN-HIV-1/VSV-G but substituted the cyto-
megalovirus (CMV) for the PGK promoter and the calcium sensor
Twitch-2B (CMV-Twitch-2B-4miR.T) for GFP. The transduction eﬃ-
ciency of Iba1+-microglia was 37% close to the injection site and 63%
in the periphery. The authors also reported transduction of neurons and
astrocytes near the epicenter and suspect that the endogenous mi-
croRNA-9 pool was insuﬃcient to counteract the strong transgene
transcription by the CMV promoter.
The latest study, by Nie et al., focused on how the toll-like receptors
(TLR) 2/4 in microglia of the prefrontal cortex contribute to social
avoidance behavior induced by repeated social defeat stress [25]. The
authors generated a transfer vector based on the PGK-GFP-4miR.T
construct and replaced the GFP with a double-ﬂoxed inverted open
reading frame (DIO) encoding mCherry and RNAi for TLR2 and TLR4
(PGK-DIO-mCherry-TLR2/4RNAi). Upon Cre-mediated recombination
of the DIO, mCherry and RNAi are expressed. The authors injected the
virus into the Cx3cr1tm2.1(cre/ERT2)Litt/WganJ mouse model [26], which
resulted in microglia-speciﬁc YFP and transgene expression after in-
jection with tamoxifen [27]. After four weeks, microglial transduction
eﬃciency was 25% and 45% for control and RNAi, respectively, and up
to 90% speciﬁc for microglia. The discrepancy between eﬃciencies in
control and RNAi transduced mice was not further addressed. This
study shows that microglial speciﬁcity can be increased by combining
Cre-mouse models with viral strategies.
In summary, all lentiviral in vivo studies thus far have taken ad-
vantage of the SIN-HIV-1/VSV-G system and adapted the promoter or
Fig. 2. Schematic of HIV genome in (a) proviral form, and lentiviral packaging system for the 2nd (b) and 3rdgeneration (c), which consists of transfer, packaging, and
envelope vector.
CMV: cytomegalovirus. cPPT: central polypurine tract, which initiates second DNA strand synthesis. Env: envelope protein. Gag: capsid components. HIV: human
immunodeﬁciency virus. LTR: long terminal repeat. PBS: primer binding site for host cell tRNAs to start reverse transcription. Pol: reverse transcriptase and integrase.
ψ: packaging signal for nucleocapsid assembling. R: tat-binding region. Rev: facilitates nuclear RNA genome export. RRE: rev responsive element, which serves as
binding site for the viral rev protein. RSV: tat-independent transcription of viral genome. Tat: initiates transcription of the viral genome. U3: RNA polymerase II
promoter for transcription of the viral genome during replication. U3Δ: mutated U3. Vif, Vpr, Vpu, Nef: virulence factors. Double arrows indicate splicing events.
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transgene cargo (Table 1).
3. Adeno-associated virus (AAV)
AAVs are part of the Parvoviridae family, and are small, non-envel-
oped viruses [28,29]. They were ﬁrst identiﬁed as a contaminant of
adenovirus-infected simian kidney cell culture [30]. Originally thought
to be a defective virus, AAVs establish a latent infection and maintain
an extra-chromosomal genome, where they can replicate autonomously
(Fig. 3) [31].
The wildtype AAV genome consists of a single-stranded DNA: rep
encodes for proteins involved in genome replication (rep78, rep68) and
virus packaging (rep52, rep40), and cap provides the viral capsid pro-
teins VP1-3 [32]. Inverted terminal repeats (ITRs) ﬂank the genome and
provide the origin of replication (Fig. 4a) [29,33,34]. For viral re-
plication, AAV depends on a helper virus like adeno- or herpes simplex
virus that encodes for enzymes critical for the lifecycle.
3.1. Design and production of AAV vectors
An estimated twelve naturally occurring AAV serotypes have been
identiﬁed, of which AAV serotype 2 (AAV2) is commonly used in re-
search [35–37]. To generate a recombinant AAV, a packaging cell line
expressing the adenoviral gene E1+ must be transfected with a
packaging vector, which supplies the rep and cap genes, a transfer
vector containing the transgene ﬂanked by ITRs, and a helper vector
encoding for E2a, E4, and VA (Fig. 4b). Importantly, the transgene size
is limited to 4.5 kb because the AAV capsid is only 20 nm in diameter,
which constrains the size of the genome [38]. AAV pseudotyping in-
creases tropism and eﬃciency: For example, AAV2/10 contains the ITR
and rep from AAV2 and cap from AAV10 [39–46].
The host cell replication machinery is required to synthesize the
complementary DNA strand. This is a rate-limiting step in the AAV
transduction process. Self-complementary AAVs (scAAVs) were devel-
oped to overcome this, although it further reduces the packaging ca-
pacity to approximately 2.2 kb, making it challenging to package a cell
type-speciﬁc promoter and a transgene-of-interest [47,48].
3.2. AAV transduction of microglia
Bartlett et al. were the ﬁrst to propose that AAVs are a viable option
for targeting microglia in vivo. They injected Cy3-labeled AAV2/2
driving GFP expression under the CMV promoter into the inferior col-
liculus and hippocampus. Cy3 was detectable in microglia after 24 h,
but microglia never expressed GFP, suggesting that the virus was either
degraded or prevented from expressing the transgene [49].
In 2003, Cucchiarini et al. sought to compare AAV2/2 and AAV2/5
transgene expression levels of RFP driven by promoters from the mac-
rophage lineages. In primary rat microglial culture, the authors describe
eﬃciencies of 25% for F4/80, 10% for CD68, and only one cell per
ﬁeld-of-view for CD11b. They then injected AAV2/5-F4/80-RFP into
the rat striatum and observed F4/80-RFP+-microglia cells, along with
other unidentiﬁed cell types [50].
To ﬁnd a more eﬀective serotype, Su et al. generated several
pseudotyped AAVs using a CMV-GFP transfer, and packaging vectors
with capsids 2, 5, 6, 8, and 9. In primary murine microglial cultures,
AAV2/6 was the most eﬀective for transducing microglia in vitro as
reported by the greatest fold change in GFP mRNA [19].
Rosario et al. modiﬁed the AAV6 capsid (AAV6™) through site-di-
rected mutagenesis of two tyrosine residues to phenylalanine and a
threonine to valine (Y731F/ Y705F/ T492V) [51]. These modiﬁcations
prevent proteasomal degradation when AAV escapes the endosomal
compartment [52–55], and has been shown to increase transduction
eﬃciency in monocyte-derived dendritic cells [52–54]. The authors
report a consistent 95% transduction eﬃciency for the scAAV2/6™-F4/
80-GFP and scAAV2/6™-CD68-GFP in primary microglia or mixed glialTa
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Fig. 3. Adeno-associated virus (AAV) production (Step I) and transduction (Step II). (1) Virus packaging cell line expressing the adenovirus E1+ is transfected with
packaging, transfer, and helper vectors. (2) Transcribed mRNA from packaging, transfer, and helper vectors are translated into (2a) viral capsid (VP1, 2, 3) and Rep,
which replicates the viral genome from the ITR (2b). (2c) The helper proteins support ﬁnal virus assembling. (3) Viral particles are released into the supernatant. (4)
Viral particles attach through interaction of the capsid with host glycan moieties, which triggers endocytosis of the particle (5). AAVs escape to the endosome by an
unknown mechanism (6), and enter the nucleus via the nuclear core complex. (7) The viral genome is released from the capsid, the double-stranded genome
synthesized (8), and an episomal circular DNA is formed (9). (10) The promoter of the transfer vector drives the expression of the transgene. ITR: inverted terminal
repeats.
Fig. 4. Schematic of (a) wildtype AAV genome and (b) AAV viral vectors system consisting of transfer, packaging, and helper vectors. AAV: adeno-associated virus.
Cap: open reading frames for proteins (VP1, VP2, VP3) which assemble into a capsid protein shell. E4, E2A, and VA: adenoviral genes necessary for AAV lifecycle.
ITR: inverted terminal repeats, which form hairpin structures. ITRΔtrs: on self-complementary genome, prevents rep-mediated nicking resulting in double-stranded
viral genome. p5, p10, p40: promoter sequences to initiate transcription. Rep: open reading frames for proteins involved in genome replication (rep78, rep68) and
packing into viral particles (rep52, rep40). trs: terminal resolution site. Double arrows indicate splicing events.
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cultures, using quantitative real-time PCR. Iba+/GFP+ microglia were
detectable with AAV2/6™ injected either into the ventricle of P0 pups or
into the adult hippocampus. The authors quantiﬁed speciﬁcity, and
emphasize in the text the exclusive labeling of microglia. However, the
graph contradicts this statement, indicating a speciﬁcity of only 75% for
F4/80 and 20% for CD68. In addition, they report a high eﬃciency in
vitro, but the in vivo eﬃciency is not quantiﬁed. Overall, this study
provides one of the ﬁrst attempts to rationally engineer AAVs to im-
prove microglial transduction in vivo.
The most recent study focused on manipulating microglia with
DREADDs (Designer Receptor Exclusively Activated by a Designer
Drug) to reverse pain response [56]. Grace et al. intrathecally trans-
duced microglia in the spinal cord with AAV2/9 containing DREADD
driven under the CD68 promoter. The authors had previously validated
this strategy and shown that DREADDs colocalize with Iba1+ cells, but
not with NeuN+ neurons or GFAP+ astrocytes [57]. Unfortunately, the
high GFP background ﬂuorescence levels make it diﬃcult to evaluate
this conclusion.
In summary, less than 20% AAV transduction eﬃciency can be
achieved in vivo (Table 2), conﬁrming that AAV transduction of mi-
croglia is challenging. This observation aligns with other publications
that have focused on improving in vivo AAV transduction for other CNS
cell types. Most approaches report a lack of microglial transduction
upon diﬀerent delivery strategies, including intrastriatal injection [44],
systemic delivery [58,59], or neonatal intracerebroventricular delivery
[40,60]. Only a few studies describe minimal microglial transduction
without further quantiﬁcation [41,61]. Although AAVs seem to be the
preferred option for targeting neurons, extensive research is still needed
to improve in vivo transduction eﬃciency in microglia.
4. Challenges on the path to successful microglial transduction
In vivo manipulation is a prerequisite to deciphering functional in-
teraction between microglia and the neuronal environment. While viral
targeting strategies have been successful in neurons, microglia remain
diﬃcult to transduce. This could be due to their endogenous macro-
phage function to detect, engulf, and destroy pathogens. Some viruses
can circumvent this defense mechanism, for example, HIV-1 can infect
microglia in the brain. To reach the nervous system, they ﬁrst infect
monocytes and use them as a trojan horse to pass the blood brain
barrier [62]. In the following section, we point out the cellular road
blocks that might prevent successful microglial transduction, and will
need future investigations. This will not only be relevant for improving
viral targeting of microglia, but will also provide critical biological
insights into host defense mechanisms.
4.1. Viral entry
Viruses exhibit high aﬃnity for deﬁned host cell receptors, pro-
viding access to the cell upon attachment. For example, the HIV-1 en-
velope glycoprotein gp160 binds the CD4 receptor and co-receptors
Cxcr4 and Ccr5 [63], the latter two are transcribed in microglia
[64,65]. Co-receptors such as the integrins Itgav and Itgb5 [66,67],
hepatocyte growth factor receptor (c-MET) [68], and ﬁbroblast growth
factor receptor 1 (FGFR1) [69,70] have been implicated in AAV at-
tachment and internalization, from which the integrins are expressed in
microglia.
Therefore, the ﬁrst step towards optimizing transduction is to screen
for microglial receptors, which are targeted by lentiviral envelopes or
AAV capsids. This would provide the building blocks for generating
pseudotyped virions. To improve attachment of the microglia-trophic
AAV2/6 and 2/9, the screening must also consider membrane glycans
on the microglial surface. The icosahedral AAV6 capsid binds to the
glycan moieties heparin sulfate proteoglycan (HSPG) and α2-3 and
α2–6 N-linked sialic acid [51,71–73], while AAV9 binds terminal N-
linked galactose [57,74]. Such knowledge would facilitate theTa
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development of further targeted mutations of HSPG binding sites on the
capsid, which has been shown to alter viral particle spread and eﬃ-
ciency in tissue tropism using AAV2/2 [44,75,76].
Although this strategy appears straightforward, a word of caution
must be raised: microglia may elicit an unexpected response similar to
macrophages. Macrophages express pattern recognition receptors
(PRRs) such as toll-like receptors or sialic acid-binding im-
munoglobulin-type lectin 1 (Siglec1). These PRRs specialize in re-
cognizing pathogen-associated molecular patterns (PAMPs) like viral
glycoprotein structures [77]. Once PRRs recognize PAMPs, they induce
a type 1-interferon response, which converts macrophages to a pro-
phagocytic state. This leads to release of pro-inﬂammatory cytokines
and, eventually, destruction of the virus [78]. Whether these mechan-
isms are also found in microglia is still under investigation, but several
studies have suggested parallels [79].
Thus far, it has been shown that microglia change their receptor
expression when they are in a prophagocytic state [80,81]. The current
viral brain delivery systems result in local tissue damage, which leads to
microglial activation [82]. On the one hand, this could be beneﬁcial for
microglial transduction since changes in the receptor distribution could
enhance viral binding. On the other hand, microglia might be locally
alerted to foreign viral particles and activate their internal viral defense
mechanism. To circumvent this, alternative viral delivery strategies
should be investigated, such as peripheral injection in the tail vein [58]
or nasal administration [83].
4.2. Viral host defense-escape mechanisms
Once the virus successfully enters the cell, the virus must control
enzymes in the host cell to ensure viral replication. Host cells, however,
have developed strategies to detect and counteract a viral invasion.
Lentivirus packages critical enzymes within the viral core, enabling
immediate reverse transcription and integration into the genome
(Fig. 1). In addition, after shedding its envelope the wildtype lentivirus
releases the virulence factors Vpx and Vif, which target the host re-
striction factors SAMHD1 and APOBEC3 that interfere with reverse
transcription and modify the reverse-transcribed viral DNA, respec-
tively [84,85]. These virulence factors have been removed from the
lentiviral vector system for biosafety reasons (Fig. 2). It would be in-
teresting to see whether microglia express SAMHD1 and APOBEC3, and
whether partially restoring the virulence factors would increase mi-
croglial transduction eﬃciency. Alternatively, drugs that prevent
SAMHD1 or APOBEC3 activation could be developed.
Speciﬁc host defense mechanisms against AAVs have not been de-
scribed. AAVs enter the cell via the endosomal pathway, but have to
escape from the endosome before its fusion with lysosomes (Fig. 3)
[86–88]. When and how AAVs leave the early or late endosome is still
debated. Similarly, the mechanism for AAV entry into the nucleus is not
known [87,89]. Only 20% of AAV2 entering the cell reaches the nu-
cleoplasm, suggesting that several unknown mechanisms exist that
prevent nuclear import [90]. Several groups have shown AAV trans-
duction eﬃciency can be enhanced in vitro by applying drugs like ba-
ﬁlomycin, which prevent endosomal acidiﬁcation by inhibiting the
proton pump [91,92]. However, such drugs cannot be used in vivo be-
cause they do not cross the blood-brain barrier, and cause severe side
eﬀects [93]. Overall, a better knowledge of the host inhibitory factors,
as well as the viral pathway to the nucleus, will signiﬁcantly improve
microglial transduction strategies.
4.3. Microglia-speciﬁc transgene expression
Speciﬁcity is another challenge faced when transducing microglia
because often, additional cells are transduced (Tables 1 and 2).
Therefore, identifying alternative constitutively expressed microglia-
speciﬁc promoters is required to optimize transgene expression. Until
now, the research ﬁeld has focused on promoters from the macrophage
lineage like CD11b, CD68, and F4/80, which also label monocytes, and
show varied expression depending on the microglial activation state.
For example, CD68 is more strongly expressed in proinﬂammatory
microglia [94]. Now, with the availability of next-generation sequen-
cing data [95–98], it should be possible to identify genes and their
corresponding promoters that are constitutively and exclusively ex-
pressed in microglia.
An alternative strategy would be to use mouse models that express
Cre in a deﬁned cell type. The transfer vector would then include the
promoter and a double-ﬂoxed inverted orientation (DIO) sequence
which is inverted upon Cre activation [99]. The tamoxifen-inducible
Cx3cr1CreERT2 mouse model has frequently been used to target micro-
glia [100]. Administering tamoxifen any time after embryonic day
E14.5 induces Cre recombinase activity in microglia, blood-derived
macrophages, and monocytes [101]. Due to their rapid turnover,
macrophages and monocytes will be replaced by non-recombined cells
within one month, leaving microglia forming more than 90% the en-
riched recombined population [27,99,101–103]. Nie et al. were one of
the ﬁrst to combine the mouse model and DIO-expressing lentivirus to
speciﬁcally target microglia [25]. They found high speciﬁcity, sug-
gesting that this is a valuable strategy for studying eﬀects in adult
microglia.
5. Lentivirus vs AAV – what can we learn?
In this review, we have focused on microglial transduction using
lentiviruses and AAVs, each posing advantages and disadvantages for
this application. Both viruses are superior to all other viral vectors (e.g.,
adeno- or pseudorabies virus) because they have low immunogenicity
and stably express transgenes without inducing cell lysis [5,6]. The
most pronounced diﬀerences are in the packaging size and host genome
integration. Lentiviruses can carry up to 9 kb genomic DNA, whereas
AAVs are restricted to 4.5 kb, which limits the ability to use cell-speciﬁc
promoters. Lentiviruses also integrate into the host genome, which re-
sults in stable transgene expression after cell division. One caveat is that
this integration occurs at random, and often in regions of actively
transcribed genes, which might trigger mutagenesis. In contrast, the
AAV genome remains predominantly episomal and shows only in-
frequent quasi-random integration [104]. Both viruses have standard
laboratory production protocols, although AAV is biosafety level 1, and
lentivirus is biosafety level 2.
We predict that addressing a combination of the aforementioned
strategies will be essential to improve eﬃciency and speciﬁcity of mi-
croglial transduction for any viral strategy. Based on the current lit-
erature, lentiviral approaches appear to be superior to AAVs, even
though only one vector system has been implemented. A cross-wise
comparison is diﬃcult due to the variation in reporting viral methods.
To improve methods for microglial transduction, and enable reprodu-
cibility, it will be important to thoroughly report all parameters for
viral vector design, production, transduction methods and experimental
quantiﬁcation. In addition, plasmids should be shared in repositories
such as Addgene to provide fast access for the entire research com-
munity. We therefore propose a guideline for best practices in reporting
microglial transduction studies to increase transparency across studies
and to ﬁnd the most eﬀective strategy to target microglia for manip-
ulation.
Guidelines for reporting viral transduction of microglia
Viral vector design and production
• Which virus was used?
○ Generation
○ Serotype/pseudotype
○ Source of packaging and envelope vectors
• What does the transfer vector encode (promoter, regulatory
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elements, transgene)?
• Which viral vector production protocol was used?
• What was the viral titer?
Viral transduction
• in vitro:
○ Which cell line?
○ If primary cell culture, which protocol?
• in vivo:
• Which animal model?
• Age, sex, strain background, genotype
• Where was the injection site?
• What anesthesia/painkiller treatment was used?
Determine viral eﬃciency and speciﬁcity
• Report eﬃciency: Cells which are transgene+ and Iba1+
against total number of Iba1+ cells
• Report speciﬁcity: Cells which are transgene+ and Iba1+
against total number of transgene+ cells
• Accompanied by a ﬁeld-of-view image of the brain region
under investigation, including detailed ﬁeld-of-view of mi-
croglial morphology.
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